Study guide
1.1 Hypertension Management in Primary Care
DHA Healthcare Professional Licensing Assessment - General Practitioner/Doctor Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Chronic Cardiovascular & Endocrine Disorders
1.1 Hypertension Management in Primary Care 1.2 Type 2 Diabetes Mellitus Management 1.3 Dyslipidemia & Thyroid Disorders
2 Chapter 2: Chronic Respiratory, Renal & Musculoskeletal Disorders
2.1 Asthma & COPD Maintenance 2.2 Chronic Kidney Disease 2.3 Chronic Musculoskeletal & Rheumatological Conditions
3 Chapter 3: Acute & Common Medical Problems
3.1 Common Infections in Primary Care 3.2 Anemia & Hematological Disorders 3.3 Acute Neurological Problems 3.4 Common Gastrointestinal Complaints
4 Chapter 4: Emergency Problems & Resuscitation
4.1 Cardiopulmonary Resuscitation & Shock 4.2 Acute Metabolic & Toxicological Emergencies 4.3 Trauma Assessment & Environmental Emergencies
5 Chapter 5: Common Pediatric Problems
5.1 Acute Pediatric Respiratory Infections 5.2 Febrile Seizures & Childhood Dehydration 5.3 Neonatal Jaundice & Pediatric Developmental Milestones
6 Chapter 6: Women's Health & Obstetric Care
6.1 Antenatal Care, Pre-eclampsia & Gestational Diabetes 6.2 Contraception & Menopause 6.3 Common Gynecological Conditions
7 Chapter 7: Common Surgical Problems
7.1 Acute Abdomen 7.2 Hernias, Hemorrhoids & Testicular Torsion 7.3 Abdominal Aortic Aneurysm & Urological Emergencies
8 Chapter 8: Common Psychiatric Problems
8.1 Mood & Anxiety Disorders 8.2 Psychosis, Delirium & Substance Use 8.3 Suicide Risk Assessment & Crisis Intervention
9 Chapter 9: Common Eye & ENT Problems
9.1 Acute Red Eye, Glaucoma & Uveitis 9.2 Otitis Media, Epistaxis & Vertigo 9.3 Common Upper Respiratory ENT Infections
10 Chapter 10: Common Dermatology Problems
10.1 Acne & Psoriasis 10.2 Eczema, Dermatitis & Skin Infections 10.3 Skin Infestations & Cutaneous Malignancies
11 Chapter 11: Family Medicine Concepts & Health Promotion
11.1 Patient-Centered Care & Continuity 11.2 Immunization & Travel Medicine 11.3 Smoking Cessation & Lifestyle Medicine
12 Chapter 12: Screening & Preventive Medicine
12.1 Cancer Screening 12.2 Cardiovascular & Metabolic Risk Screening
13 Chapter 13: Epidemiology, EBM, Ethics & UAE Regulations
13.1 Basic Epidemiology & Outbreak Measures 13.2 Evidence-Based Medicine & Study Designs 13.3 Professionalism, Ethics & UAE Regulations
1.1 Hypertension Management in Primary Care
Key Takeaways Explain This Topic AI
Diagnosis of hypertension requires at least two readings on two or more separate clinical visits, or home blood pressure monitoring to rule out white-coat and masked hypertension.
ACC/AHA blood pressure guidelines define Stage 1 hypertension as 130-139 / 80-89 mmHg and Stage 2 as >=140 / >=90 mmHg, with a universal target of <130/80 mmHg.
Thiazide diuretics like Chlorthalidone can cause hypokalemia, hyponatremia, hypercalcemia, and hyperuricemia, which may precipitate acute gouty arthritis.
In patients with diabetes and albuminuria (UACR >= 30 mg/g), the target blood pressure is <130/80 mmHg, and an ACE inhibitor or ARB is mandated as first-line therapy.
When starting or increasing ACE inhibitors or ARBs, check serum creatinine and potassium in 1-2 weeks; a creatinine increase of up to 30% from baseline is acceptable.
Last updated: July 2026
Hypertension Management in Primary Care
Hypertension remains the leading modifiable risk factor for cardiovascular disease, stroke, and chronic kidney disease (CKD) worldwide. Effective management in primary care requires rigorous diagnostic protocols, patient-centered risk stratification, and evidence-based pharmacotherapy aligned with clinical guidelines.
1. Diagnostic Criteria and Classification
Accurate blood pressure (BP) measurement is the foundation of hypertension management. A diagnosis should never be established based on a single office reading, unless the patient presents with a hypertensive crisis (systolic BP >= 180 mmHg or diastolic BP >= 120 mmHg) or clear signs of acute target-organ damage.
Diagnostic Protocol
To confirm a diagnosis:
Clinical Assessment: Obtain at least two readings on two or more separate office visits.
Proper Technique: The patient must sit quietly for >= 5 minutes, back supported, feet flat on the floor, and the arm supported at heart level. Avoid caffeine, exercise, and smoking for >= 30 minutes before measurement. Use an appropriately sized cuff (bladder length >= 80% and width >= 40% of arm circumference).
Out-of-Office Confirmation: Utilize Ambulatory Blood Pressure Monitoring (ABPM) or Home Blood Pressure Monitoring (HBPM) to rule out white-coat hypertension (elevated in office, normal at home) or masked hypertension (normal in office, elevated at home).
Guideline Comparisons and Classification
Current guidelines display slight variations in thresholds and target goals, particularly when comparing the classic Joint National Committee (JNC 8) guidelines with newer consensus statements from the American College of Cardiology/American Heart Association (ACC/AHA 2017) and the European Society of Cardiology/European Society of Hypertension (ESC/ESH).
- BP Category (ACC/AHA) Systolic BP (mmHg) Diastolic BP (mmHg)
- Normal < 120 and < 80
- Elevated 120–129 and < 80
- Stage 1 Hypertension 130–139 or 80–89
- Stage 2 Hypertension >= 140 or >= 90
JNC 8 differs significantly by maintaining the threshold for Stage 1 hypertension at >= 140/90 mmHg for adults under 60, and >= 150/90 mmHg for those aged 60 and older.
2. Guideline Recommendations and Treatment Targets
The therapeutic target for blood pressure reduction depends on the guidelines utilized:
ACC/AHA (2017): Recommends a universal target of < 130/80 mmHg for all patients, including those with diabetes mellitus, CKD, or older adults (>= 65 years old) living independently.
JNC 8: Suggests a target of < 140/90 mmHg for patients under 60, diabetics, and those with CKD. For patients >= 60 without diabetes or CKD, the target is relaxed to < 150/90 mmHg .
ESC/ESH (2018): Recommends an initial target of < 140/90 mmHg for all, titrated down to < 130/80 mmHg if well-tolerated, but not below 120/70 mmHg.
3. Pharmacological Management: The Four Core Drug Classes
For primary hypertension without compelling indications, four drug classes are established as first-line agents: Angiotensin-Converting Enzyme Inhibitors (ACEi), Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers (CCBs), and Thiazide/Thiazide-like diuretics.
A. Angiotensin-Converting Enzyme Inhibitors (ACEi)
Mechanism: Inhibit the angiotensin-converting enzyme, preventing the conversion of Angiotensin I to the potent vasoconstrictor Angiotensin II. This leads to systemic vasodilation and decreased aldosterone secretion.
Clinical Value: Highly effective in reducing cardiovascular events. They are the drug of choice in patients with type 2 diabetes, chronic kidney disease (CKD), heart failure with reduced ejection fraction (HFrEF), and post-myocardial infarction.
Adverse Effects: Dry cough (due to accumulation of bradykinin in the respiratory tract), hyperkalemia, acute kidney injury (AKI), and life-threatening angioedema.
Contraindications: Pregnancy (teratogenic), history of angioedema, and bilateral renal artery stenosis (where renal perfusion is highly dependent on Angiotensin II-mediated efferent arteriolar vasoconstriction).
B. Angiotensin Receptor Blockers (ARBs)
Mechanism: Selectively block the Angiotensin II Type 1 (AT1) receptors, preventing the actions of Angiotensin II.
Clinical Value: Indicated for the same patient profiles as ACEi. They serve as the primary alternative for patients who develop an ACEi-induced dry cough, as they do not affect bradykinin metabolism.
Contraindications: Identical to ACEi. Crucially, ACEi and ARBs should never be combined due to a significantly increased risk of hyperkalemia, syncope, and acute kidney injury without any additional cardiovascular benefit.
C. Calcium Channel Blockers (CCBs)
CCBs are divided into two distinct chemical and clinical classes:
Dihydropyridines (e.g., Amlodipine, Nifedipine): Primarily act on vascular smooth muscle to cause arterial vasodilation.
Adverse Effects: Dose-dependent peripheral edema (caused by precapillary dilation, not volume overload), flushing, headache, and reflex tachycardia.
Non-dihydropyridines (e.g., Diltiazem, Verapamil): Act primarily on the cardiac myocardium and conduction system.
Clinical Value: Used for rate control in atrial fibrillation, flutter, or angina.
Adverse Effects: Bradycardia, AV block, constipation (especially verapamil), and worsening heart failure. They are contraindicated in patients with HFrEF due to negative inotropic effects.
D. Thiazide and Thiazide-like Diuretics
Mechanism: Inhibit the Na+/Cl- cotransporter in the distal convoluted tubule, promoting sodium and water excretion.
Agents: Chlorthalidone is preferred over Hydrochlorothiazide (HCTZ) because it is longer-acting (half-life of 40–60 hours vs. 6–15 hours) and has demonstrated superior reduction in cardiovascular events in large clinical trials.
Adverse Effects: Characterized by metabolic changes:
Increases (Hyper-): Hyperglycemia, Hyperuricemia (precipitating acute gout flares), Hypercalcemia, and Hyperlipidemia.
Decreases (Hypo-): Hypokalemia, Hyponatremia, and Hypomagnesemia.
4. Special Populations: Diabetes and CKD with Albuminuria
Patients with diabetes mellitus and chronic kidney disease who exhibit albuminuria (defined as a urine albumin-to-creatinine ratio [UACR] >= 30 mg/g) represent a high-risk group.
Therapeutic Strategy
Blood Pressure Target: A strict target of < 130/80 mmHg is recommended to preserve renal function and reduce cardiovascular mortality.
Preferred Agent: An ACEi or ARB must be initiated as first-line therapy, regardless of the patient's race or baseline blood pressure. These agents dilate the renal efferent arteriole to a greater extent than the afferent arteriole, decreasing intraglomerular hydrostatic pressure. This mechanism directly reduces the filtration of proteins and halts the progression of glomerulosclerosis.
Clinical Monitoring: Serum creatinine and potassium levels must be measured within 1–2 weeks of initiating or escalating the dose of an ACEi or ARB.
A serum creatinine increase of up to 30% from baseline is hemodynamically expected and acceptable, representing the therapeutic drop in intraglomerular pressure.
If creatinine rises > 30% , or if serum potassium exceeds 5.5 mEq/L , the medication should be held or dose-reduced, and the patient evaluated for underlying bilateral renal artery stenosis.
Loading diagram...